Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,646 total articles
EchoStar CORP (NASDAQ:SATS) President of Technology and COO John Swieringa sold 50,088 shares of Class A Common Stock on March 4, 2026, in two tranches for roughly $5.69 million and exercised options that same day to acquire 35,088 shares at $16.57 each. The transactions leave Swieringa with 253,535 directly held shares and 809 indirectly held via …
Baker Hughes CEO Lorenzo Simonelli sold 272,593 shares of Class A common stock on March 4, 2026 for about $16.6 million and on the same day exercised options to buy 187,343 shares at $35.70, costing roughly $6.7 million. The trades were conducted under a Rule 10b5-1 plan and follow a quarter in which the company beat expectations and arranged multi…
Nextpower Inc. Chief Executive Officer Daniel S. Shugar sold 39,892 shares on March 4, 2026, for roughly $4.03 million under a pre-established 10b5-1 plan. An analysis indicates the stock is trading above estimated fair value despite a 144% one-year return. On March 6, 2026, Shugar completed reciprocal transfers with the Kathleen and Daniel Shugar …
NMI Holdings Executive Chairman Bradley M. Shuster sold 19,430 shares on March 5, 2026, for $755,943 and on March 4 exercised options to acquire 55,158 shares at $11.10. The transactions leave Shuster with direct ownership of 415,411 shares plus 47,150 shares held by the Shuster Family Trust. The moves come as the company reports a fourth-quarter 2…
Jennifer Fitzpatrick, Chief Legal Officer of Sionna Therapeutics, sold 10,250 shares of common stock on March 5, 2026, under a pre-arranged Rule 10b5-1 plan and exercised options to acquire an identical number of shares. The stock has advanced to $36, with sizeable gains over multiple time horizons, while recent analyst updates and an InvestingPro …
Madrigal Pharmaceuticals President and CEO William John Sibold sold 1,663 shares on March 6 to satisfy tax-withholding obligations tied to restricted stock units, generating proceeds of $718,316. The sale was non-discretionary, according to a SEC Form 4 filing. Madrigal recently reported a fourth-quarter 2025 earnings-per-share shortfall even as re…
Energy Recovery Chief Technology Officer Natarajan Ramanan sold 272 shares of the company’s common stock on March 5, 2026, for $10.57 per share, a transaction valued at $2,875. The sale was filed on a Form 4 with the Securities and Exchange Commission and was executed under a power of attorney, with William Yeung signing on Ramanan’s behalf. The tr…
LTC Properties director David L. Gruber acquired 7,000 shares of common stock on March 5, 2026, spending $266,000 at $38.00 per share. The transaction comes as the REIT trades close to its 52-week high and amid mixed quarterly results that included an EPS beat-in-line and a substantial revenue miss, as LTC pursues Senior Housing Operating Partnersh…
Madrigal Pharmaceuticals' general counsel, Kelley Shannon T, sold 360 shares on March 6, 2026, for $431.94 each, totaling $155,498. Recent SEC filings show additional stock activity and option grants earlier in March, while the company reported a Q4 2025 earnings shortfall on EPS but revenue above expectations and continued strong sales from its le…
Kinetik Holdings Inc. (NASDAQ: KNTK) Chief Financial Officer Trevor Howard sold 1,619 shares of Class A common stock on March 4, 2026, in a Form 4 filing. The shares were sold at $46.92 each for a total of $75,963 to satisfy tax withholding tied to vested shares awarded in lieu of cash for the 2025 annual incentive. After the sale Howard directly o…
Lindsay Ellis, Kinetik Holdings Inc.'s General Counsel, Chief Compliance Officer and Corporate Secretary, sold 1,260 shares of Class A common stock on March 4, 2026, to satisfy tax-withholding obligations tied to the vesting of equity awards. The trade totaled $59,119 at $46.92 per share. The transaction occurs amid a 29% year-to-date share gain an…
Steven Stellato, Kinetik Holdings Inc.'s executive vice president, chief accounting officer and administrative officer, sold 2,907 shares of Class A Common Stock on March 4, 2026, at $46.92 per share, resulting in proceeds of $136,396. The transaction was conducted to satisfy tax withholding tied to the vesting of shares issued in lieu of cash for …
Suma Krishnan, a director and President, R&D at Krystal Biotech, sold 23,799 shares of the company's common stock on March 4, 2026, in a series of transactions that generated roughly $6.58 million in proceeds. The disposals were executed under a Rule 10b5-1 trading plan adopted in September 2025. Separately, Krystal Biotech reported fourth-quarter …
Kinetik Holdings Inc. Chief Operating Officer Matthew Wall sold 3,222 Class A shares on March 4, 2026 to satisfy tax withholding tied to the vesting of compensation from the 2025 annual incentive award. The transaction totaled $151,176 based on a $46.92 sale price. The stock is trading around $45.60 and has risen 29% year-to-date amid mixed quarter…
MaxLinear Inc. Chief Financial Officer and Chief Corporate Strategy Officer Steven G. Litchfield reported sales of company stock totaling $746,427 over three consecutive days in early March 2026, according to a Form 4 filing. The transactions reduced his direct holdings to 343,435 shares. The share sales occurred amid recent downward pressure on th…
Yelp Chief Operating Officer Joseph R. Nachman executed a pre-arranged sale of 2,499 shares on March 6, 2026, for roughly $60,450, according to a Form 4 filing. The transaction followed a recent grant of performance-based restricted stock units and comes amid active share repurchases, a recent quarterly beat, tempered guidance, and divergent analys…
FormFactor Inc. CFO and SVP Global Finance Aric Brendan McKinnis sold 3,462 shares on March 5, 2026 under a Rule 10b5-1 plan, generating $313,034. The transaction follows recent share price swings even as the company reported better-than-expected fourth-quarter results and carries a market capitalization of $6.59 billion.
Tidewater Inc. Executive Vice President, Chief Financial Officer and Chief Administrative Officer Rubio Samuel R sold 22,461 shares of Tidewater common stock on March 5, 2026, generating proceeds of $1,798,003. The transaction occurred at prices between $80.01 and $80.51. The sale follows a year in which Tidewater shares have climbed nearly 90% and…
Daniel A. Hudson, Executive Vice President and General Counsel of Tidewater (NYSE:TDW), sold 5,195 shares of the company's common stock on March 5, 2026 for a total of $418,509. The transaction occurred amid Tidewater's stronger-than-expected fourth-quarter 2025 financial performance and a Raymond James price-target increase to $117.
Sheri B. Bronstein, Bank of America’s Chief People Officer, sold 60,000 shares on March 5, 2026, generating $2.99 million at weighted average prices between $49.65 and $50.24. The bank has several concurrent capital and strategic actions, including a Yen-denominated note redemption, new bond issuance, a role in an IPO, a data partnership with the L…
Innospec Executive Vice President and CFO Ian Cleminson sold 2,380 shares of the company's common stock on February 27, 2026, through a series of transactions priced between $75.5001 and $77.0713. The sales totaled approximately $182197. After the trades, Cleminson retains direct ownership of 20,357 Innospec shares. The firm's stock has fallen abou…
Steven B. Klinsky, a director at New Mountain Finance Corp (NASDAQ: NMFC), purchased 237,873 shares of the company on March 5, 2026, at $8.10 per share, a transaction valued at $1,926,771. The stock was trading at $7.98 at the time of reporting, with New Mountain Finance maintaining a market capitalization of $807 million. The Form 4 filing details…
BridgeBio Pharma director Andrea Ellis sold 64,921 shares on March 4, 2026, for $4,211,301 under a Rule 10b5-1 plan while exercising options to acquire the same number of shares at $8.45 each. The company reported Q4 revenue above estimates driven by Attruby sales, recorded a larger-than-expected adjusted loss, and said interim Phase 3 FORTIFY data…
Quest Diagnostics Senior Vice President Karthik Kuppusamy sold 2,628 shares on March 4, 2026, at $204.86 per share for about $538,372 and on the same day received 6,200 shares valued at $1,270,132 as settlement of a performance stock award. The transactions took place with shares trading close to a 52-week high; the company recently reported strong…
Christopher Gustanski, Phinia Inc.'s vice president of Operational Excellence, sold 3,812 shares of common stock on March 4, 2026, in a transaction valued at $277,239. The sale came as Phinia reported fourth-quarter 2025 results that beat on revenue but missed on earnings per share. At the time of reporting, the company's share price was lower than…
